Chapter 669

(House Bill 641)

AN ACT concerning

Hepatitis B and Hepatitis C Viruses – Public Awareness, Treatment, and Outreach

FOR the purpose of requiring the Department of Health and Mental Hygiene, as funds are available, to conduct a certain needs assessment, initiate a certain statewide public awareness campaign, solicit certain funding, and review and recommend certain initiatives related to the hepatitis B virus; requiring the Department, as funds are available, to coordinate with the Maryland Office of Minority Health and Health Disparities to activate develop certain hepatitis B virus and hepatitis C virus plans; requiring the Department, as funds are available, to develop a certain plan and certain recommendations and to collaborate with the Maryland Insurance Administration to make certain recommendations regarding certain insurance coverage; requiring the Maryland Health Care Commission to examine certain research findings and make a certain report to the Governor and certain committees of the General Assembly on or before a certain date; repealing the termination date for provisions of law that require the Department to conduct certain outreach and public awareness campaigns and make certain reports regarding the hepatitis C virus; and generally relating to public awareness, treatment, and outreach relating to the hepatitis B and hepatitis C viruses.

BY repealing and reenacting, with amendments,
   Article – Health – General
   Section 18–1001
   Annotated Code of Maryland
   (2009 Replacement Volume and 2011 Supplement)

BY repealing and reenacting, without amendments,
   Article – Health – General
   Section 18–1002
   Annotated Code of Maryland
   (2009 Replacement Volume and 2011 Supplement)

BY repealing and reenacting, with amendments,
   Section 4

Preamble

– 1 –
WHEREAS, There are approximately 5,300,000 individuals with hepatitis B, hepatitis C, or both living in the United States; and

WHEREAS, Hepatitis B and hepatitis C are viral infections that attack the liver and can cause both acute and chronic disease; and

WHEREAS, One in 20 Americans has been infected with hepatitis B; and

WHEREAS, The Centers for Disease Control has recognized hepatitis B as the deadliest vaccine–preventable disease; and

WHEREAS, Hepatitis C is three to four times more prevalent than human immunodeficiency virus (HIV) and is much more infectious than HIV; and

WHEREAS, Hepatitis B and hepatitis C disproportionately affect minority populations, including African Americans, Hispanics, American Indian/Native Americans as well as Asian and Pacific Islanders; and

WHEREAS, The annual health care costs attributable to hepatitis B are estimated to be approximately $2,000 per infected individual and the annual health care costs attributable to treating hepatitis C with protease inhibitors are approximately $30,000 per infected individual; and

WHEREAS, Direct antibodies treatment of hepatitis C, a newer treatment, is associated with a 91% to 94% cure rate; and

WHEREAS, Hepatitis B and hepatitis C patients who progress to end–stage liver disease may require treatments costing between $30,980 and $110,576 per hospital admission, and hepatitis B and hepatitis C patients who are diagnosed too late may require a liver transplant costing at least $314,000; and

WHEREAS, The Centers for Disease Control has revised its vaccine recommendations to include vaccination at birth, vaccination of all previously unvaccinated children and adolescents, and vaccination of previously unvaccinated adults at risk for hepatitis B infection in an effort to eliminate hepatitis B from the United States; and

WHEREAS, There is no vaccination for hepatitis C; and

WHEREAS, According to the Institute of Medicine, hepatitis B and hepatitis C infections cause substantial morbidity and mortality despite being preventable and treatable; now, therefore,

SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, That the Laws of Maryland read as follows:
As funds are available, the Department shall:

(1) Conduct a needs assessment to determine the incidence of the 
HEPATITIS B VIRUS AND hepatitis C virus in the State;

(2) Initiate a statewide public awareness campaign targeting 
vulnerable populations and health care providers in the State to urge 
HEPATITIS B VIRUS AND hepatitis C virus education and testing;

(3) Coordinate with other units of State government, including the 
Department of Public Safety and Correctional Services and the Veterans’ 
Administration, to activate a hepatitis C virus plan for the education, testing, and 
treatment of the populations within the jurisdiction of the units;

(4) Solicit funding from the private sector and units of federal, state, 
and local government for 
HEPATITIS B VIRUS AND hepatitis C virus outreach;

(5) Provide funding for hepatitis C virus pilot programs, which may 
include programs in methadone clinics or programs for the Department of Correctional 
Services population;

(6) Review and recommend initiatives to promote advocacy, education, 
physician outreach, and awareness of the 
HEPATITIS B VIRUS AND hepatitis C virus;

(7) Assess the feasibility of creating a Hepatitis C Virus 
Administration in the Department and examine methods to maximize existing 
resources to raise awareness of the hepatitis virus; [and]

(8) Implement the 2005 Report of the Hepatitis C Advisory Council;

(9) COORDINATE WITH THE MARYLAND OFFICE OF MINORITY 
HEALTH AND HEALTH DISPARITIES TO DEVELOP AND ACTIVATE A HEPATITIS B 
VIRUS PLAN AND A HEPATITIS C VIRUS PLAN FOR THE EDUCATION, TESTING, 
AND TREATMENT OF HIGH RISK POPULATIONS AND ETHNIC AND RACIAL 
POPULATIONS WHO ARE AFFECTED DISPROPORTIONATELY BY THE HEPATITIS B 
AND HEPATITIS C VIRUSES, INCLUDING THE ASIAN POPULATION AND AFRICAN 
IMMIGRANTS;

(10) DEVELOP A PLAN TO INCREASE THE AVAILABILITY AND 
PROVISION OF HEPATITIS B VIRUS VACCINATIONS IN THE STATE, IN
ACCORDANCE WITH RECOMMENDATIONS FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION;

(11) DEVELOP RECOMMENDATIONS TO IMPROVE THE AWARENESS AND THE AFFORDABILITY OF MEDICATIONS FOR TREATING THE HEPATITIS C VIRUS; AND

(12) COLLABORATE WITH THE MARYLAND INSURANCE ADMINISTRATION TO MAKE RECOMMENDATIONS REGARDING INSURANCE COVERAGE FOR COMPLICATIONS ASSOCIATED WITH MEDICATIONS USED FOR THE TREATMENT OF THE HEPATITIS C VIRUS.

18–1002.

On or before December 1, 2006, and annually thereafter, the Department shall report to the Governor and, in accordance with § 2–1246 of the State Government Article, to the Senate Education, Health, and Environmental Affairs Committee and the House Health and Government Operations Committee on the activities of the Department in implementing § 18–1001 of this subtitle.


SECTION 4. AND BE IT FURTHER ENACTED, That this Act shall take effect July 1, 2006. [Section 2 of this Act shall remain effective for a period of 7 years and, at the end of June 30, 2013, with no further action required by the General Assembly, Section 2 of this Act shall be abrogated and of no further force and effect.]

SECTION 2. AND BE IT FURTHER ENACTED, That the Maryland Health Care Commission shall:

(1) examine existing research findings related to health disparities in the effectiveness of medical treatment of African Americans with hepatitis C and make recommendations for collect recommended protocols for treating African Americans who have hepatitis C from experts in the field; and

(2) on or before December 1, 2012, report its findings and recommendations to the Governor and, in accordance with § 2–1246 of the State Government Article, to the Senate Education, Health, and Environmental Affairs Committee and the House Health and Government Operations Committee.

SECTION 3. AND BE IT FURTHER ENACTED, That this Act shall take effect July 1, 2012.
Approved by the Governor, May 22, 2012.